Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

Members of the writing committee (Emily Y. Chew, M.D. [chair], National Eye Institute, National Institutes of Health [NIH], Bethesda, MD; Walter T. Ambrosius, Ph.D., Wake Forest University School of Medicine, Winston-Salem, NC; Matthew D. Davis, M.D., Ronald P. Danis, M.D., and Sapna Gangaputra, M.D., M.P.H., University of Wisconsin, Madison; Craig M. Greven, M.D., Wake Forest University School of Medicine, WinstonSalem, NC; Larry Hubbard, M.A.T., and Barbara A. Esser, M.S., University of Wisconsin, Madison; James F. Lovato, M.S., Letitia H. Perdue, B.A., and David C. Goff, Jr., M.D., Ph.D., Wake Forest University School of Medicine, WinstonSalem, NC; William C. Cushman, M.D., Veterans Affairs Medical Center, Memphis; Henry N. Ginsberg, M.D., Columbia University College of Physicians and Surgeons, New York; Marshall B. Elam, M.D., Ph.D., Veterans Affairs Medical Center, Memphis; Saul Genuth, M.D., Case Western Reserve University, Cleveland; Hertzel C. Gerstein, M.D., McMaster University, Hamilton, ON, Canada; Ulrich Schubart, M.D., Albert Einstein College of Medicine, Bronx, NY; and Lawrence J. Fine, M.D., National Heart, Lung, and Blood Institute, NIH, Bethesda, MD) assume responsibility for the integrity of the article. Address reprint requests to Dr. Chew at the National Institutes of Health, Bldg. 10, Clinical Research Center, Rm. 3-2531, 10 Center Dr., Mail Stop Center 1204, Bethesda, MD 20892, or at [email protected].